10.11.2022 SHOP APOTHEKE EUROPE N.V.  NL0012044747

EQS-News: At the VISION 2045 Summit alongside the COP 27: CEO Stefan Feltens presents SHOP APOTHEKE EUROPE’s NET ZERO 2040 Strategy in Sharm El Sheikh.


 

EQS-News: SHOP APOTHEKE EUROPE N.V. / Key word(s): Sustainability
At the VISION 2045 Summit alongside the COP 27: CEO Stefan Feltens presents SHOP APOTHEKE EUROPE’s NET ZERO 2040 Strategy in Sharm El Sheikh.

10.11.2022 / 09:00 CET/CEST
The issuer is solely responsible for the content of this announcement.


At the VISION 2045 Summit alongside the COP 27:
CEO Stefan Feltens presents SHOP APOTHEKE EUROPE’s NET ZERO 2040 Strategy in Sharm El Sheikh.

Sevenum, November 10, 2022. From 07 to 09 November 2022, the second corporate conference Vision 2045 Summit took place in conjunction with the UN Climate Change Conference COP27. In the panel "Climate Legacy" CEO Stefan Feltens officially introduced SHOP APOTHEKE EUROPE’s climate protection strategy NET ZERO 2040.

The three-day conference in Sharm El Sheikh, Egypt, brought together a global delegation of political, business and industry leaders to collaboratively develop strategies for a fair and sustainable society. This second summit, hosted by TBD Media Group, was held in parallel with the 27th United Nations Climate Change Conference (COP 27) and featured approximately 50 companies as well as United Nations delegates from all over the world working to further advance climate protection.

SHOP APOTHEKE EUROPE participated for the first time as a representative of the healthcare industry to present its climate protection strategy. With this declaration, the company firmly commits to meeting the 1.5°C target on the way to NET ZERO 2040, thereby acting in alignment with the Paris Climate Agreement. SHOP APOTHEKE EUROPE relies on the XDC Model, software and metrics developed by right°, to help calculate and manage this science-based target and ensure that the emissions budget is not exceeded in the process. SHOP APOTHEKE EUROPE has so far been able to achieve significant successes in the area of sustainability. For instance, it is apparent that the company is likely to achieve its self-imposed targets for 2025 - such as reducing emissions in Scope 1 and 2 by 80% and converting its logistics sites to 100% renewable energy - as early as this year. Pilot projects to reduce Scope 3 emissions are already in progress.

CEO Stefan Feltens comments: "As one of Europe's leading e-pharmacies, it is important to us that we take responsibility for our planet– for the sake of our customers and patients as well as our employees, who are not afraid to communicate their expectations clearly to us. In order to live up to our mission to enable everyone to live the healthiest life possible, we depend on a healthy planet. With our NET ZERO Strategy 2040, we are making a clear and strong statement. But now the real work starts."

Watch the video on Sustainable Development at SHOP APOTHEKE EUROPE here:
https://shop-apotheke-europe.com/en/sustainability/.

 

ABOUT SHOP APOTHEKE EUROPE.

SHOP APOTHEKE EUROPE is one of Europe’s leading and fastest-growing online pharmacies, currently operating in Germany, Austria, France, Belgium, Italy, the Netherlands and Switzerland.

Headquartered in the Dutch logistics hub of Sevenum near Venlo with locations in Cologne, Berlin, Munich, Tongeren, Warsaw, Milan, Lille and Eindhoven, SHOP APOTHEKE EUROPE offers its customers a broad range of more than 100,000 original products at attractive prices: OTC, beauty and personal care products as well as prescription drugs, supplemented by high quality natural food and health products, low carb products and sports nutrition. Currently, 8.9 million active customers trust SHOP APOTHEKE EUROPE.

Since safe and reliable pharmaceutical advice are top priorities at SHOP APOTHEKE EUROPE, the e-pharmacy provides comprehensive pharmaceutical consulting services. In preparation for the full introduction of the electronic prescriptions in Germany, the company is continuously expanding in the area of digital health services.

SHOP APOTHEKE EUROPE N.V. has been listed on the regulated market of the Frankfurt Stock Exchange (Prime Standard) since 2016 and is part of the SDAX stock index.



10.11.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: SHOP APOTHEKE EUROPE N.V.
Erik de Rodeweg 11-13
5975 WD Sevenum
Netherlands
Phone: 0800 - 200 800 300
Fax: 0800 - 90 70 90 20
E-mail: [email protected]
Internet: www.shop-apotheke-europe.com
ISIN: NL0012044747, DE000A19Y072
WKN: A2AR94, A19Y07
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1483719

 
End of News EQS News Service

1483719  10.11.2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1483719&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023
Umsatzerlöse1 283,99 539,71 701,01 968,06 1.060,32 1.204,35 1.798,76
EBITDA1,2 -12,14 -15,56 -18,58 15,20 -38,73 -29,66 39,99
EBITDA-Marge3 -4,27 -2,88 -2,65 1,57 -3,65 -2,46
EBIT1,4 -19,20 -28,73 -33,45 -0,87 -65,70 -69,17 -17,30
EBIT-Marge5 -6,76 -5,32 -4,77 -0,09 -6,20 -5,74 -0,96
Jahresüberschuss1 -21,36 -33,61 -36,27 -16,77 -74,19 -77,65 -11,61
Netto-Marge6 -7,52 -6,23 -5,17 -1,73 -7,00 -6,45 -0,65
Cashflow1,7 -23,24 -23,54 -30,37 17,80 11,64 -29,11 61,46
Ergebnis je Aktie8 -2,25 -2,79 -2,78 -1,17 -4,15 -4,32 -0,73
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2023 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Forvis Mazars

INVESTOR-INFORMATIONEN
©boersengefluester.de
Redcare Pharmacy
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A2AR94 143,000 Halten 2.908,98
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
79,44 0,00 0,00 -68,49
KBV KCV KUV EV/EBITDA
5,57 47,33 1,62 76,84
Dividende '22 in € Dividende '23 in € Div.-Rendite '23
in %
Hauptversammlung
0,00 0,00 0,00 17.04.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
25.04.2024 30.07.2024 05.11.2024 05.03.2024
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
4,19% 8,04% 9,16% 17,02%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu SHOP APOTHEKE EUROPE N.V.  ISIN: NL0012044747 können Sie bei EQS abrufen


E-Commerce , A2AR94 , RDC , XETR:RDC